Meriofert Pfs (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

The drug contains human LH and FSH which bind to their respective receptors on ovarian cells. This binding activates signaling pathways that promote follicle growth, estradiol production, ovulation, and luteal phase support, thereby restoring normal reproductive hormone activity.

The dose of Meriofert Pfs is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s specific condition, response to treatment, and monitoring results.

Meriofert Pfs is intended for use before conception to achieve pregnancy. Its safety in established pregnancy or while breastfeeding has not been established, and it should only be used under specialist supervision when pregnancy is planned.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and required import documentation.

Meriofert Pfs combines both LH and FSH activity, whereas some alternatives contain only FSH. The dual activity can provide more physiologic stimulation for certain protocols, but the choice depends on the clinician’s assessment of the patient’s hormonal profile and treatment goals.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discoloured or particulate.

Meriofert Pfs is given by a healthcare professional as an intramuscular or subcutaneous injection. The injection site and technique are selected according to the prescribed regimen and patient comfort.

The most serious risks include severe ovarian hyperstimulation syndrome, thromboembolic events, anaphylactic reactions, multiple pregnancy, and ovarian cyst rupture. Patients should be monitored closely for signs of these complications throughout treatment.

Meriofert Pfs is contraindicated in individuals with known hypersensitivity to human LH or FSH, uncontrolled ovarian cysts, active thromboembolic disease, or those who are pregnant. It should also be used with caution in patients with severe ovarian failure where stimulation is unlikely to be effective.